Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GRI

Profil Institute appoints former Amylin CEO

Dan Bradbury joins board of diabetes company

- PMLiVE

Novo enrols first patient in Tresiba cardiovascular trial

Milestone comes as diabetes-focused company reports solid growth

- PMLiVE

Novo Nordisk recalls insulin

Batches of prefilled NovoMix 30 pens found to have incorrect amount of diabetes treatment

- PMLiVE

Sanofi launches a monster mobile diabetes game

Monster Manor iPhone and Android apps aim to encourage better management of the condition

- PMLiVE

Novo Nordisk wins US approval for haemophilia treatment

NovoEight will be launched alongside MixPro device after gaining FDA licence

- PMLiVE

Third try for MannKind’s inhaled insulin

Pharma company resubmits regulatory filing for diabetes treatment Afrezza in the US

- PMLiVE

Novo’s Wagtmann joins Innate as chief scientific officer

He was previously head of inflammation biology at Danish pharma company

- PMLiVE

Novo backs Victoza’s prospects in Alzheimer’s

Chief science officer says phase III trial could begin in three years

- PMLiVE

EASD 2013: Novo Nordisk’s diabetes combination IDegLira impresses in study

Mix of Tresiba and Victoza helps 81 per cent achieve blood sugar target in phase III

Sanofi reception

EASD 2013: Sanofi prepared for biosimilar threat to Lantus

Next generation insulin U300 set to launch at time of patent expiration

- PMLiVE

EASD 2013: Sanofi justifies decision to withdraw US filing for Lyxumia

Takes issue with FDA's narrow risk-benefit focus

- PMLiVE

Boehringer launches integrated Hispanic diabetes campaign

Creative development overseen Miami-based agency Republica

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links